RSRamnath Subbaraman

Ramnath Subbaraman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ramnath Subbaraman has a total of 288 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond land tenure and titling: legal recognition as a pivotal determinant of health in urban informal settlements

    by Alice Sverdlik, Smith Ouma, Saloni Dev, Anita Patil-Deshmukh, Michelle Koyaro, Zilire Luka, Ramnath Subbaraman

  • Open Access

    Perceptions of sources of transmission among hospital employees infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) in an urban tertiary care hospital: a qualitative study to inform future pandemic management

    by Ziyue Luo, Daniel E. Kent, Pooja Shah, Dina Poplausky, MacKenzie Clark MacRae, Cassidy Boomsma, Jacob M. Jasper, Alysse G. Wurcel, Elena Byhoff, Alice M. Tang, et al.

    Objective: Hospital employees are at risk of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection from patient, coworker, and community interactions. Understanding employees’ perspectives on transmission risks may inform hospital pandemic management strategies. Design: Qualitative interviews were conducted with 23 employees to assess factors contributing to perceived transmission risks during patient, coworker, and community interactions and to elicit recommendations. Using a deductive approach, transcripts were coded to identify recurring themes. Setting: Tertiary hospital in Boston, Massachusetts. Participants: Employees with a positive SARS-CoV-2 PCR test between March 2020 and January 2021, a period before widespread vaccine availability. Results: Employees generally reported low concern about transmission risks during patient care. Most patient-related risks, including limited inpatient testing and personal protective equipment availability, were only reported during the early weeks of the pandemic, except for suboptimal masking adherence by patients. Participants reported greater perceived transmission risks from coworkers, due to limited breakroom space, suboptimal coworker masking, and perceptions of inadequate contact tracing. Perceived community risks were related to social gatherings and to household members who also had high SARS-CoV-2 infection risk because they were essential workers. Recommendations included increasing well-ventilated workspaces and breakrooms, increasing support for sick employees, and stronger hospital communication about risks from non-patient-care activities, including the importance of masking adherence with coworkers and in the community. Conclusions: To reduce transmission during future pandemics, hospitals may consider improving communication on risk reduction during coworker and community interactions. Societal investments are needed to improve hospital infrastructure (eg, better ventilation and breakroom space) and increase support for sick employees.

  • Open Access

    Contextual factors influencing implementation of tuberculosis digital adherence technologies: a scoping review guided by the RE-AIM framework

    by Shruti Bahukudumbi, Chimweta I Chilala, Nicola Foster, Barbie Patel, Mona S Mohamed, Miranda Zary, Cedric Kafie, Genevieve Gore, Kevin Schwartzman, Katherine L Fielding, et al.

    Introduction: Digital adherence technologies (DATs) may enable person-centred tuberculosis (TB) treatment monitoring; however, implementation challenges may undermine their effectiveness. Using the reach, effectiveness, adoption, implementation and maintenance framework, we conducted a scoping review to identify contextual factors informing ‘reach’ (DAT engagement by people with TB) and ‘adoption’ (DAT uptake by healthcare providers or clinics). Methods: We searched eight databases from 1 January 2000 to 25 April 2023 to identify all TB DAT studies. After extracting qualitative and quantitative findings, using thematic synthesis, we analysed common findings to create meta-themes informing DAT reach or adoption. Meta-themes were further organised using the Unified Theory of Acceptance and Use of Technology, which posits technology use is influenced by perceived usefulness, ease of use, social influences and facilitating conditions. Results: 66 reports met inclusion criteria, with 61 reporting on DAT reach among people with TB and 27 reporting on DAT adoption by healthcare providers. Meta-themes promoting reach included perceptions that DATs improved medication adherence, facilitated communication with providers, made people feel more ‘cared for’ and enhanced convenience compared with alternative care models (perceived usefulness) and lowered stigma (social influences). Meta-themes limiting reach included literacy and language barriers and DAT technical complexity (ease of use); increased stigma (social influences) and suboptimal DAT function and complex cellular accessibility challenges (facilitating conditions). Meta-themes promoting adoption included perceptions that DATs improved care quality or efficiency (perceived usefulness). Meta-themes limiting adoption included negative DAT impacts on workload or employment and suboptimal accuracy of adherence data (perceived usefulness); and suboptimal DAT function, complex cellular accessibility challenges and insufficient provider training (facilitating conditions). Limitations of this review include the limited studies informing adoption meta-themes. Conclusion: This review identifies diverse contextual factors that can inform improvements in DAT design and implementation to achieve higher engagement by people with TB and healthcare providers, which could improve intervention effectiveness.


  • Open Access

    Implementation outcomes of tuberculosis digital adherence technologies: a scoping review using the RE-AIM framework

    by Chimweta I Chilala, Nicola Foster, Shruti Bahukudumbi, Mona Salaheldin Mohamed, Miranda Zary, Cedric Kafie, Barbie Patel, Genevieve Gore, Kevin Schwartzman, Ramnath Subbaraman, et al.

    Introduction: Globally, tuberculosis (TB) remains one of the leading infectious causes of death, with 1.3 million deaths. Digital adherence technologies (DATs) have the potential to provide person-centred care and improve outcomes. Using the reach, effectiveness, adoption, implementation and maintenance (RE-AIM) framework, we conducted a scoping review of DAT implementations for TB treatment. Methods: We searched seven databases for papers published between January 2000 and April 2023, using keywords for ‘tuberculosis’ and ‘digital adherence technology’. Articles meeting prespecified inclusion criteria and containing data on RE-AIM domains were included. We defined ‘reach’ as comprising cellphone ownership and engagement by people with TB (PWTB) with DATs, ‘adoption’ as engagement by healthcare providers with DAT programmes, ‘implementation’ as the fidelity of the DAT programme implemented and ‘maintenance’ as longer-term uptake of DATs. Results: Of 10 313 records, 102 contributed to the synthesis. DATs included short message service (SMS), phone, 99DOTS, video-supported therapy (VST) and pillboxes. For ‘reach’, across various settings, cellphone access varied from 50%–100% and 2%–31% of PWTB was excluded from accessing DATs due to technology challenges. 36%–100% of PWTB agreed to use a DAT. The weighted mean of DAT engagement over dose-days was 81% for SMS, 85% for phone, 61% for 99DOTS, 87% for pillbox and 82% for VST. Concerning ‘implementation’, the fidelity of DAT implementations was affected by technological issues such as cellphone coverage, DAT malfunction and provider-facing issues, including failure to initiate intensified patient management following low DAT engagement. Findings related to RE-AIM dimensions of ‘adoption’ and ‘maintenance’ were limited. Conclusion: Our findings suggest that the ‘reach’ of DATs may be limited by a cascade of barriers, including limitations in cellphone accessibility and suboptimal sustained DAT engagement by PWTB. Video and pillbox DATs have higher levels of engagement. Implementation challenges included technological and provider-facing issues. Improving implementation outcomes may be important for TB DATs to achieve a broader public health impact. PROSPERO registration number: CRD42022326968


  • Open Access

    Cost and cost-effectiveness of digital technologies for support of tuberculosis treatment adherence: a systematic review

    by Cedric Kafie, Mona Salaheldin Mohamed, Miranda Zary, Chimweta Ian Chilala, Shruti Bahukudumbi, Genevieve Gore, Nicola Foster, Katherine L Fielding, Ramnath Subbaraman, Kevin Schwartzman

    Background Digital adherence technologies (DATs) may provide a patient-centred approach to supporting tuberculosis (TB) medication adherence and improving treatment outcomes. We synthesised evidence addressing costs and cost-effectiveness of DATs to support TB treatment. Methods A systematic review (PROSPERO-CRD42022313531) identified relevant literature from January 2000 to April 2023 in MEDLINE, Embase, CENTRAL, CINAHL, Web of Science along with preprints from medRxiv, Europe PMC and ClinicalTrials.gov. Studies with observational, experimental or quasi-experimental designs (minimum 20 participants) and modelling studies reporting quantitative data on the cost or cost-effectiveness of DATs for TB infection or disease treatment were included. Study characteristics, cost and cost-effectiveness outcomes were extracted. Results Of 3619 titles identified by our systematic search, 29 studies met inclusion criteria, of which 9 addressed cost-effectiveness. DATs included short message service (SMS) reminders, phone-based technologies, digital pillboxes, ingestible sensors and video-observed therapy (VOT). VOT was the most extensively studied (16 studies) and was generally cost saving when compared with healthcare provider directly observed therapy (DOT), particularly when costs to patients were included—though findings were largely from high-income countries. Cost-effectiveness findings were highly variable, ranging from no clinical effect in one study (SMS), to greater effectiveness with concurrent cost savings (VOT) in others. Only eight studies adequately reported at least 80% of the elements required by Consolidated Health Economic Evaluation Reporting Standards, a standard reporting checklist for health economic evaluations. Conclusion DATs may be cost saving or cost-effective compared with healthcare provider DOT, particularly in high-income settings. However, more data of higher quality are needed, notably in lower-income and middle-income countries which have the greatest TB burden.


  • Open Access

    The performance of digital technologies for measuring tuberculosis medication adherence: a systematic review

    by Miranda Zary, Mona Salaheldin Mohamed, Cedric Kafie, Chimweta Ian Chilala, Shruti Bahukudumbi, Nicola Foster, Genevieve Gore, Katherine L Fielding, Ramnath Subbaraman, Kevin Schwartzman

    Introduction Digital adherence technologies (DATs), such as phone-based technologies and digital pillboxes, can provide more person-centric approaches to support tuberculosis (TB) treatment. However, there are varying estimates of their performance for measuring medication adherence. Methods We conducted a systematic review (PROSPERO—CRD42022313526), which identified relevant published literature and preprints from January 2000 to April 2023 in five databases. Studies reporting quantitative data on the performance of DATs for measuring TB medication adherence against a reference standard, with at least 20 participants, were included. Study characteristics and performance outcomes (eg, sensitivity, specificity and predictive values) were extracted. Sensitivity was the proportion correctly classified as adherent by the DAT, among persons deemed adherent by a reference standard. Specificity was the proportion correctly classified as non-adherent by the DAT, among those deemed non-adherent by a reference standard. Results Of 5692 studies identified by our systematic search, 13 met inclusion criteria. These studies investigated medication sleeves with phone calls (branded as ‘99DOTS’; N=4), digital pillboxes N=5), ingestible sensors (N=2), artificial intelligence-based video-observed therapy (N=1) and multifunctional mobile applications (N=1). All but one involved persons with TB disease. For medication sleeves with phone calls, compared with urine testing, reported sensitivity and specificity were 70%–94% and 0%–61%, respectively. For digital pillboxes, compared with pill counts, reported sensitivity and specificity were 25%–99% and 69%–100%, respectively. For ingestible sensors, the sensitivity of dose detection was ≥95% compared with direct observation. Participant selection was the most frequent potential source of bias. Conclusion The limited number of studies available suggests suboptimal and variable performance of DATs for dose monitoring, with significant evidence gaps, notably in real-world programmatic settings. Future research should aim to improve understanding of the relationships of specific technologies, settings and user engagement with DAT performance and should measure and report performance in a more standardised manner.


  • Open Access

    Contextual factors influencing implementation of tuberculosis digital adherence technologies: a scoping review guided by the RE-AIM framework

    by Shruti Bahukudumbi, Chimweta I. Chilala, Nicola Foster, Barbie Patel, Mona S. Mohamed, Miranda Zary, Cedric Kafie, Genevieve Gore, Kevin Schwartzman, Katherine Fielding, et al.

    Introduction Digital adherence technologies (DATs) may enable person-centered tuberculosis (TB) treatment monitoring; however, implementation challenges may undermine their effectiveness. Using the RE-AIM framework, we conducted a scoping review to identify contextual factors informing “reach” (DAT engagement by people with TB) and “adoption” (DAT uptake by healthcare providers or clinics). Methods We searched eight databases from January 1, 2000 to April 25, 2023 to identify all TB DAT studies. After extracting qualitative and quantitative findings, using thematic synthesis, we analyzed common findings to create meta-themes informing DAT reach or adoption. Meta-themes were further organized using the Unified Theory of Acceptance and Use of Technology, which posits technology use is influenced by perceived usefulness, ease of use, social influences, and facilitating conditions. Results 66 reports met inclusion criteria, with 61 reporting on DAT reach among people with TB and 27 reporting on DAT adoption by healthcare providers. Meta-themes promoting reach included perceptions that DATs improved medication adherence, facilitated communication with providers, made people feel more “cared for,” and enhanced convenience compared to alternative care models (perceived usefulness); and lowered stigma (social influences). Meta-themes limiting reach included literacy and language barriers and DAT technical complexity (ease of use); increased stigma (social influences); and suboptimal DAT function and complex cellular accessibility challenges (facilitating conditions). Meta-themes promoting adoption included perceptions DATs improved care quality or efficiency (perceived usefulness). Meta-themes limiting adoption included negative DAT impacts on workload or employment and suboptimal accuracy of adherence data (perceived usefulness); and suboptimal DAT function, complex cellular accessibility challenges, and insufficient provider training (facilitating conditions). Limitations of this review include the limited studies informing adoption meta-themes. Conclusion This review identifies diverse contextual factors that can inform improvements in DAT design and implementation to achieve higher engagement by people with TB and healthcare providers, which could improve intervention effectiveness. What is already known on this topic Digital adherence technologies (DATs) are increasingly used to monitor TB treatment; however, systematic reviews suggest DATs have mixed effectiveness for improving TB outcomes and suboptimal accuracy for measuring medication adherence. Inadequate DAT “reach” (engagement by people with TB) and “adoption” (uptake by healthcare providers) may contribute to their limited effectiveness and accuracy. Understanding contextual factors influencing DAT reach and adoption may be critical to improve the design, implementation, and public health impact of TB DATs. What this study adds Our findings show people with TB value DATs when they improve adherence, enhance communication with providers, enhance convenience of care, and reduce stigma. People with TB are less likely to engage with DATs in settings with barriers to cellular accessibility or when DATs are not designed for their literacy level, are technically complex, have suboptimal function, or increase stigma. TB healthcare providers value DATs when they improve care quality or efficiency. Healthcare providers are less likely to engage in settings with barriers to cellular accessibility or when DATs increase workloads, threaten employment, provide inaccurate adherence data, or have suboptimal function. How this study might affect research, practice, or policy Our findings may inform future design of DATs to focus on what people with TB value, such as improved communication with providers and convenience of care. Our findings may also help to identify settings in which DATs are unlikely to be effective, such as locations where cellular accessibility barriers are substantial due to poor infrastructure.


  • Open Access

    Barriers to engagement in the care cascade for tuberculosis disease in India: A systematic review of quantitative studies

    by Tulip A. Jhaveri, Disha Jhaveri, Amith Galivanche, Maya Lubeck-Schricker, Dominic Voehler, Mei Chung, Pruthu Thekkur, Vineet Chadha, Ruvandhi Nathavitharana, Ajay M. V. Kumar, et al.

    Background: India accounts for about one-quarter of people contracting tuberculosis (TB) disease annually and nearly one-third of TB deaths globally. Many Indians do not navigate all care cascade stages to receive TB treatment and achieve recurrence-free survival. Guided by a population/exposure/comparison/outcomes (PECO) framework, we report findings of a systematic review to identify factors contributing to unfavorable outcomes across each care cascade gap for TB disease in India. Methods and findings: We defined care cascade gaps as comprising people with confirmed or presumptive TB who did not: start the TB diagnostic workup (Gap 1), complete the workup (Gap 2), start treatment (Gap 3), achieve treatment success (Gap 4), or achieve TB recurrence-free survival (Gap 5). Three systematic searches of PubMed, Embase, and Web of Science from January 1, 2000 to August 14, 2023 were conducted. We identified articles evaluating factors associated with unfavorable outcomes for each gap (reported as adjusted odds, relative risk, or hazard ratios) and, among people experiencing unfavorable outcomes, reasons for these outcomes (reported as proportions), with specific quality or risk of bias criteria for each gap. Findings were organized into person-, family-, and society-, or health system-related factors, using a social-ecological framework. Factors associated with unfavorable outcomes across multiple cascade stages included: male sex, older age, poverty-related factors, lower symptom severity or duration, undernutrition, alcohol use, smoking, and distrust of (or dissatisfaction with) health services. People previously treated for TB were more likely to seek care and engage in the diagnostic workup (Gaps 1 and 2) but more likely to suffer pretreatment loss to follow-up (Gap 3) and unfavorable treatment outcomes (Gap 4), especially those who were lost to follow-up during their prior treatment. For individual care cascade gaps, multiple studies highlighted lack of TB knowledge and structural barriers (e.g., transportation challenges) as contributing to lack of care-seeking for TB symptoms (Gap 1, 14 studies); lack of access to diagnostics (e.g., X-ray), non-identification of eligible people for testing, and failure of providers to communicate concern for TB as contributing to non-completion of the diagnostic workup (Gap 2, 17 studies); stigma, poor recording of patient contact information by providers, and early death from diagnostic delays as contributing to pretreatment loss to follow-up (Gap 3, 15 studies); and lack of TB knowledge, stigma, depression, and medication adverse effects as contributing to unfavorable treatment outcomes (Gap 4, 86 studies). Medication nonadherence contributed to unfavorable treatment outcomes (Gap 4) and TB recurrence (Gap 5, 14 studies). Limitations include lack of meta-analyses due to the heterogeneity of findings and limited generalizability to some Indian regions, given the country’s diverse population. Conclusions: This systematic review illuminates common patterns of risk that shape outcomes for Indians with TB, while highlighting knowledge gaps—particularly regarding TB care for children or in the private sector—to guide future research. Findings may inform targeting of support services to people with TB who have higher risk of poor outcomes and inform multicomponent interventions to close gaps in the care cascade.


  • Putting technology to the test in tuberculosis care

    by Ramnath Subbaraman, Katherine Fielding


  • Open Access

    The Impact of Digital Adherence Technologies on Health Outcomes in Tuberculosis: A Systematic Review and Meta-Analysis

    by Mona Salaheldin Mohamed, Miranda Zary, Cedric Kafie, Chimweta Ian Chilala, Shruti Bahukudumbi, Nicola Foster, Genevieve Gore, Katherine Fielding, Ramnath Subbaraman, Kevin Schwartzman

    Background: Suboptimal tuberculosis (TB) treatment adherence may lead to unsuccessful treatment and relapse. Digital adherence technologies (DATs) may allow more person-centric approaches for supporting treatment. We conducted a systematic review (PROSPERO-CRD42022313166) to evaluate the impact of DATs on health outcomes in TB. Methods: We searched MEDLINE, Embase, CENTRAL, CINAHL, Web of Science and preprints from medRxiv, Europe PMC, and clinicaltrials.gov for relevant literature from January 2000 to April 2023. We considered experimental or cohort studies reporting quantitative comparisons of clinical outcomes between a DAT and the standard of care in each setting. Results: Seventy studies (total 58,950 participants) met inclusion criteria. They reported SMS-based interventions (k=18 studies), feature phone-based interventions (k=7), medication sleeves with phone calls (branded as “99DOTS,” k=5), video-observed therapy (VOT; k=17), smartphone-based interventions (k=5), digital pillboxes (k=18), ingestible sensors (k=1), and interventions combining 2 DATs (k=1). Overall, the use of DATs was associated with more frequent treatment success in TB disease (OR = 1.18 [1.06, 1.33]; I 2 = 66%, k = 46), a decrease in loss to follow up (OR = 0.71 [0.53, 0.94]; I 2 = 80%, k = 36) and an increase in adverse event reporting (OR = 1.53 [1.26, 1.86]; I 2 = 0%, k = 9). VOT was associated with an increased likelihood of treatment success in TB disease (OR 1.54 [1.09; 2.19]; I 2 = 0%, k = 8) and treatment completion in TB infection (OR 4.69 [2.08; 10.55]; I 2 = 0%, k = 2) as well as an increased frequency of adverse event reporting (OR = 1.79 [1.27; 2.52]; I 2 = 34%, k = 4). Other interventions involving smartphone technologies were associated with increased treatment success in TB disease (OR 1.98 [1.07; 3.65]; I 2 =56%, k = 5) and a decreased frequency of loss to follow up (OR = 0.31 [0.13; 0.77]; I 2 = 36%, k = 5). Digital pillboxes were also associated with an improvement in treatment success (OR = 1.32 [1.00; 1.73]; I 2 = 71%, k = 11). However, improved treatment success was only seen in high- and upper middle-income countries. SMS-based interventions, feature-phone interventions and 99DOTS were not associated with improvements in short-term clinical outcomes. Conclusion: Certain DATs--notably VOT and smartphone-based interventions, in higher income settings and sometimes combined with other supportive measures—may be associated with improvements in treatment success and losses to follow-up, compared to standard care. However, evidence remains highly variable, and generalizability limited. Higher quality data are needed.